Stock listing
Frankfurt:8LY OncoZenge AB Aktie
German listing (Frankfurt) of OncoZenge AB · home listing Stockholm:ONCOZ
Follow OncoZenge AB into a list and get an email when it puts out news.
Share price · FWB:8LY
€0.259 EUR -0.016 (-5.7%)
Close on Oct 30, 2026
- Day range
- €0.259 – €0.259 EUROct 30, 2026
- Market cap
- €6.48M EURAt the close on Oct 30, 2026 · price × 25.05M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:ONCOZ · Home | 3.105 SEK | -0.005 (-0.2%) | 86,625 | 3.115 | 3.345 | 2.89 | 3.11 | Close on Nov 2, 2026 |
| Frankfurt:8LY | €0.259 EUR | -0.016 (-5.7%) | — | €0.259 | €0.259 | €0.259 | €0.274 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:8LY
- Asset type
- Stock
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 23, 2026
OncoZenge: Rights issue concludes at ~92% subscription
Latest news
Financings
Rights offering of shares
Sep 22, 2026 · US$3.12M
Closed: SEK 30.7M raised · SEK 3 a share · Vator Securities AB +1
Dealers: Vator Securities AB, Stockholm Corporate Finance AB
Buyers: LINC AB (subscription commitment of SEK 2,633,865 (7.9%)); Andreas Adnan Özbek (subscription commitment of SEK 1,423,125 (4.3%)); Stian Kildal (CEO; subscription commitment of SEK 1,125,000 (3.4%), privately and through companies); Paul Murtagh through Fenix Dental AB (subscription commitment of SEK 270,000 (0.8%)); M Owens Management Consulting AB (subscription commitment of SEK 22,500 (0.07%)); Life Science Invest Fund (stands behind the guarantee through put option agreements with the guarantor)
Insiders: Board members, senior management and certain larger shareholders committed to subscribe approximately SEK 5.5 million, about 16.4 percent of the Rights Issue
Use of proceeds: Complete the Phase III BupiZenge trial and extend runway (65%), MAA preparations (25%), general corporate purposes, business development and IP (10%)
Announced Aug 25, 2026 · Update Sep 18, 2026 · Closed Sep 22, 2026
Bridge loan
Aug 28, 2026 · US$208,669
Closed: SEK 2M raised
Buyers: John Haurum (bridge loan of SEK 2.0 million, which he may request be set off against new shares at the Rights Issue subscription price)
Use of proceeds: To secure the Company's liquidity requirements until the approximately SEK 33.3 million rights issue is completed
Private placement of shares
Aug 21, 2026 · US$528,343
Tranche closed: SEK 5M raised · SEK 6.47 a share
Buyers: Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (directed share issue of approximately SEK 15.1 million; partial payment of SEK 5.0 million made); Sichuan Yangtian Bio-Pharmaceutical Co, Ltd (remaining subscription proceeds of approximately SEK 10.1 million to be paid)
Update Jul 10, 2026 · Update Aug 14, 2026 · Tranche closed Aug 21, 2026
OncoZenge AB on 6ix
- News releases
- 33 in the last 12 months · 34 in all · newest Sep 23, 2026 · oldest 2025
Where OncoZenge AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:ONCOZ · Home listing | Stockholm | Sweden | SEK |
| Frankfurt:8LY · This page | Frankfurt | Germany | EUR |
Log in to ask 6ix AI your own questions about OncoZenge AB.